Zonagen Reports Breast Cancer Tumor Inhibitory Effects of Progenta in Animal Model.Business Editors/Health/Medical Writers THE WOODLANDS, Texas--(BUSINESS WIRE)--March 30, 2004 Zonagen, Inc. (Nasdaq:ZONA) announced that Dr. Ronald Wiehle, the Company's Director of R&D, is presenting today data generated at Zonagen in collaboration with scientists at the University of Illinois-Chicago that indicate the potential for Progenta(TM) for the treatment of breast cancer. The data is being presented at the 2004 Annual Meeting of the American Association for Cancer Research Wikipedia is not the place for advertisement or self-advertising. The American Association for Cancer Research (AACR) is an organization based in Philadelphia, Pennsylvania, that focuses on all aspects of cancer research including basic, clinical and translational being held in Orlando, Florida The city of Orlando is a major city in central Florida and is the county seat of Orange County, Florida. According to the 2000 census, the city population was 185,951. A 2006 U.S. . The poster presentation elaborates upon the Company's recent finding that Progenta(TM) shows significant activity against hormone-dependent breast cancer induced in rats by DMBA DMBA 9,10-Dimethylbenz-A-Anthracene . DMBA is a tumor-inducing agent used in a well-accepted breast cancer tumor model. In the study, rats were given DMBA at 50 days of age and entered randomly into treatment groups when the lead tumor reached 12 mm in size. Groups of 10-13 rats were treated for 28 days with vehicle (oil) or with varying doses of Progenta(TM) with or without progesterone progesterone (prōjĕs`tərōn'), female sex hormone that induces secretory changes in the lining of the uterus essential for successful implantation of a fertilized egg. . Progenta(TM) reduced the size of established tumors significantly and prevented the appearance of new tumors over the course of the treatment period. The strong anti-tumor effects seen with Progenta(TM) correlated with suppression of growth and increased apoptosis, or programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the , by immunohistochemistry. Whereas progesterone enhanced tumor growth, Progenta(TM) was very effective in promoting tumor regression. This work was funded via a Phase I Small Business Research grant (SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ). The Company is in the process of requesting additional government funding through a Phase II grant to further elucidate these effects before considering a human clinical program for the indication. In addition, Zonagen is currently preparing the necessary documentation to seek approval to begin a European Phase I/II study of Progenta(TM) for the treatment of uterine fibroids Uterine Fibroids Definition Uterine fibroids (also called leiomyomas or myomas) are benign growths of the muscle inside the uterus. They are not cancerous, nor are they related to cancer. . ABOUT ZONAGEN Zonagen is engaged in the development of pharmaceutical products that address diseases and conditions associated with the human reproductive system The human reproductive system consists of:
Any statements that are not historical facts contained in this release are forward-looking statements that involve risks and uncertainties including Zonagen's ability to have success in the clinical development of its technologies, Zonagen's ability to raise additional capital on acceptable terms or at all, uncertainty relating to Zonagen's patent portfolio, Zonagen's ability to have success in meeting governmental regulations and the costs and time required to meet such regulatory requirements, manufacturing uncertainties related to Progenta, the Company's ability to remain listed on Nasdaq, and such other risks identified in Zonagen's Annual Report on Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2003, as filed with the Securities and Exchange Commission (SEC). These documents are available on request from Zonagen or at www.sec.gov. Zonagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion